Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

CHAPTER TWO: INTRODUCTION

• Introduction
• History and Growth of the Cancer Treatment Market
• Types of Vaccines
  • Antigen/Adjuvant Vaccines
  • Whole Cell Tumor Vaccines
  • Dendritic Cell (DC) Vaccines
  • Viral Vectors and DNA Vaccines
  • Idiotype Vaccines
• Types of Therapeutic Vaccines
  • Patient-Specific Vaccines
  • Prostate Specific Antigen
  • Sialyl Tn
  • Heat Shock Proteins
  • Ganglioside Molecules
  • Carcinoembryonic Antigen (CEA)
  • MART-1
  • Tyrosinase
  • Adjuvants
• Industry Structure
• Demographics and Statistics
  • Growing and Aging Population
  • Life Expectancy and Cancer

CHAPTER THREE: CERVICAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • Gardasil/Silgard
  • Cervarix
• Description of Vaccines in Development
  • TG 4001/R3484
  • HspE7
  • Lovaxin C
  • VGX-3100
  • CA-9
• Market Summary
• Current and Potential Competitors and Analysis, 2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • OncoVAX
• Description of Vaccines in Development
  • OncoVAX
  • TroVAX
  • Avicine
  • CEA VRP Vaccine
  • Collidem
  • IMA910
  • Lapuleucel-T
  • Oncophage
  • CDX-1307-01
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER FIVE: LUNG CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • Lucanix
  • MAGE-A3 Peptide
  • Stimuvax
  • EGF Cancer Vaccine
  • GV-1001
  • HyperAcute Lung
  • IDM 2101 (EP-2101)
  • Oncophage
  • INGN 225
  • TG 4010
  • LungVAX
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • DC Vax
  • L523S
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER SIX: LYMPHOMA VACCINES

• Overview
• Description of Vaccines in Development
  • MyVax
  • BiovaxID
  • FavId
  • TG 1042
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER SEVEN: MELANOMA VACCINES

• Overview
• Description of Vaccines on the Market
• Description of Vaccines in Development
  • M-VAX
  • GMK
  • Allovectin-7
  • MDX-1379 with Combination Treatment MDX-010
  • Oncophage
  • MAGE-A3 ASCI 3
  • Uvidem
  • AGI-101H Vaccine
  • ALVAC Vaccine
  • HyperAcute Melanoma
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • Provenge
  • DCVax-Prostate
  • GVAX
  • ProstAtak
  • TroVAX
  • Telomerase Cancer Vaccine
  • MVA-BN Prostate
  • HyperAcute Prostate
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER NINE: BREAST CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • INGN 225
  • CEA VRP Vaccine
  • MVA-BN HER2
  • Lapuleucel-T
  • PX 104.1
  • CDX-1307-02
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • GV 1001
  • GI-4000
  • Avicine
  • GVAX
  • HyperAcute Pancreas
  • Oncophage
  • CDX-1307-01
  • CRS-100
  • CRS-207
  • DC Vax
  • MKC1106-PP
• Market Summary

CHAPTER ELEVEN: RENAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • Oncophage
• Description of Vaccines in Development
  • Oncophage
  • Reniale
  • TroVAX
  • IMA901
  • AGS-003
  • MDX-1106
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER TWELVE: BRAIN CANCER VACCINES

• Overview
  • Glioblastoma
  • Neuroblastoma
• Description of Vaccines in Development
  • DCVax-Brain
  • CDX-110
  • GliAtak
  • Oncophage
• Market Summary

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)
• Description of Vaccines in Development
  • Bexidem
  • CG0070
  • MDX-1307-01
• Market Summary

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • OVax Autologous Cell Vaccine
  • Lapuleucel-T
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary

CHAPTER FIFTEEN: LEUKEMIA VACCINES

• Overview
• Description of Vaccines in Development
  • GVAX
  • PR1 Peptide Vaccine
  • AGS-005
• Market Summary

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

• Introduction
• Early Detection and Screening
• Monoclonal Antibodies and Therapeutic Vaccines
• Political and Social Pressure
• Insurance and Reimbursement Issues
• Personalized Medicine
• Pharmacogenomics
• Vaccine Strategies
• New Genetic Technique
• Future Growth in Vaccines

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

• Overview
• Total Market Size and Forecast
• Market and Competitor Analysis

CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES

• Introduction
• Antigenics, Inc
• Avax Technologies, Inc
• Biovest International, Inc
• Cell Genesys, Inc
• Dendreon Corporation
• Genitope Corporation
• GlaxoSmithKline plc
• Merck & Company, Inc
• Northwest Biotherapeutics, Inc
• NovaRx
• Oncothyreon
• Vaccinogen
• Vical, Inc

CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
• Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012

CHAPTER TWO: INTRODUCTION

• Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
• Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
• Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
• Figure 2-2: Total Cancer Incidence by Sex and Country
• Table 2-3: World Population by Selected Geographical Region, 2007-2050
• Figure 2-4: World Population by Selected Geographical Region, 2007-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2007
• Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
• Table 2-5: Percent Population Over 65 by Year and Region
• Figure 2-5: Estimated World Population by Age, 2007 and 2050
• Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
• Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
• Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

CHAPTER THREE: CERVICAL CANCER VACCINES

• Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
• Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
• Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
• Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
• Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
• Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

• Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
• Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
• Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
• Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
• Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
• Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012

CHAPTER FIVE: LUNG CANCER VACCINES

• Table 5-1: Types of Primary Lung Cancer
• Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
• Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
• Table 5-3: Lung Cancer Vaccines in the Pipeline

CHAPTER SIX: LYMPHOMA VACCINES

• Table 6-1: Classification of Non-Hodgkin' s Lymphomas
• Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
• Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
• Table 6-3: Lymphoma Vaccines in the Pipeline
• Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
• Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
• Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012

CHAPTER SEVEN: MELANOMA VACCINES

• Table 7-1: Malignant Condidtions of the Skin
• Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
• Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
• Table 7-3: Melanoma Vaccines in the Pipeline
• Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
• Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
• Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES

• Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
• Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
• Table 8-2: Prostate Cancer Vaccines in the Pipeline
• Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
• Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
• Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012

CHAPTER NINE: BREAST CANCER VACCINES

• Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
• Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
• Table 9-2: Breast Cancer Vaccines in the Pipeline

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

• Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
• Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
• Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline

CHAPTER ELEVEN: RENAL CANCER VACCINES

• Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
• Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
• Table 11-2: Renal Cancer Vaccines in the Pipeline
• Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
• Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
• Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012

CHAPTER TWELVE: BRAIN CANCER VACCINES

• Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
• Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
• Table 12-2: Brain Cancer Vaccines in the Pipeline

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

• Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
• Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
• Table 13-2: Bladder Cancer Vaccines in the Pipeline

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

• Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
• Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
• Table 14-2: Ovarian Cancer Vaccines in the Pipeline

CHAPTER FIFETEEN: LEUKEMIA VACCINES

• Table 15-1: TYPES OF LEUKEMIA
• Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
• Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
• Table 15-3: Leukemia Vaccines in the Pipeline

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

• Table 16-1: Cancer Detection Tests

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

• Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012
• Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
• Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012

CANCER VACCINE CORPORATE PROFILES

COMPANY NAMES AND ADDRESSES